Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01184
|
|||||
| Drug Name |
Nitric oxide
|
|||||
| Synonyms |
HNO; ()NO; 10102-43-9; AC1L3QHF; Bioxyde d'azote; Bioxyde d'azote [French]; CHEBI:16480; CHEMBL1200689; CTK0H7679; DTXSID1020938; EDRF; Endogenous Nitrate Vasodilator; Endothelium-Derived Nitric Oxide; Endothelium-derived relaxing factor (EDRF); INOmax; INOmax (TN); Mononitrogen monoxide; Monoxide, Mononitrogen; Monoxide, Nitrogen; Monoxido de nitrogeno; Monoxyde d'azote; NITRIC-OXIDE; NO(); Nitrate Vasodilator, Endogenous; Nitric Oxide, Endothelium Derived; Nitric Oxide, Endothelium-Derived; Nitric oxide; Nitric oxide (JAN); Nitric oxide 10% by volume or more; Nitric oxide trimer; Nitric oxide, 985%; Nitric oxide, compressed [UN1660] [Poison gas]; Nitrogen monoxide; Nitrogen oxide (NO); Nitrogen(II) oxide; Nitrosoradical; Nitrosyl; Nitrosyl hydride; Nitrosyl hydride ((NO)H); Nitrosyl radical; Nitroxide radical; Nitroxyl; OHM 11771; Oxide, Nitric; Oxido de nitrogeno(II); Oxido nitrico; Oxidonitrogen; Oxoazanyl; Oxyde azotique; Oxyde nitrique [French]; Stickmonoxyd; Stickmonoxyd [German]; Stickstoff(II)-oxid; Stickstoffmonoxid; Vasodilator, Endogenous Nitrate; [NO]; endothelium-derived relaxing factor; monoxido de nitrogeno; monoxyde d'azote; nitric oxide; nitrogen monoxide; nitrogen protoxide; nitrosyl; oxido de nitrogeno(II); oxido nitrico; oxidonitrogen; oxoazanyl; oxyde azotique
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Platelet dysfunction [ICD11: 3B62] | Phase 2/3 | [1] | |||
| Therapeutic Class |
Bronchodilator Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
NO
|
|||||
| Canonical SMILES |
[N]=O
|
|||||
| InChI |
InChI=1S/NO/c1-2
|
|||||
| InChIKey |
MWUXSHHQAYIFBG-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 10102-43-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 30.006 | Topological Polar Surface Area | 18.1 | ||
| Heavy Atom Count | 2 | Rotatable Bond Count | 0 | |||
| Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 1 | |||
| XLogP |
0.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10248789
, 10322712
, 10502255
, 11532572
, 11532575
, 11533089
, 11538857
, 11538865
, 14715948
, 3009
, 3815
, 584758
, 584760
, 585304
, 612541
, 6435917
, 6436059
, 6436465
, 7847142
, 8009073
, 8024763
, 8025088
, 819430
, 819437
, 823106
, 825225
, 827786
, 827830
, 829083
, 829196
, 830346
, 831905
, 832739
, 832741
, 832746
, 832749
, 835684
, 835924
, 835946
, 835951
, 837432
, 837589
, 838043
, 838516
, 838735
, 838738
, 838741
, 841103
, 854516
, 854518
|
|||||
| ChEBI ID |
ChEBI:16480
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | ASCT2 | Transporter Info | Alanine/serine/cysteine/threonine transporter 2 | Substrate | [2] | |
| References | ||||||
| 1 | ClinicalTrials.gov (NCT03455218) Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation | |||||
| 2 | Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett. 2005 Apr 25;579(11):2499-506. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.